Anti-tim-3 antigen antibody or antibody derivative, and use thereof
US-2024391997-A1 · Nov 28, 2024 · US
Compositions and methods for treating proliferative disorders
US9447185B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9447185-B2 |
| Application number | US-8931406-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 13, 2006 |
| Priority date | Oct 14, 2005 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a patient with ulcerative colitis, Crohn's disease, psoriasis, or spondyloarthropathy, comprising: administering to said patient a therapeutically effective amount of one or more antibodies that each specifically binds to a receptor selected from KIR2DL1, KIR2DS1, KIR2DL2, KIR2DL3, KIR2DS4, and KIR3DL2 expressed on a T cell and/or a NK cell, wherein the one or more antibodies each comprises an F c region of the human IgG1 or human IgG3 isotype capable of binding to CD16. 2. The method of claim 1 , wherein said antibody does not comprise an element selected from the group consisting of a radioactive isotope, toxic peptide, and toxic small molecule. 3. The method according to claim 1 , wherein said receptor is KIR3DL2. 4. A method for reducing inflammation in a patient with ulcerative colitis, Crohn's disease, psoriasis, or spondyloarthropathy, comprising administering to said patient a composition comprising a therapeutically effective amount of an antibody that specifically binds to a receptor selected from KIR2DL1, KIR2DS1, KIR2DL2, KIR2DL3, KIR2DS4, and KIR3DL2 expressed on a T cell and/or a NK cell, wherein the antibody comprises an F c region of the human IgG1 or human IgG3 isotype capable of binding to CD16. 5. The method according to claim 4 , wherein said antibody specifically binds to KIR3DL2. 6. The method of claim 4 , wherein said antibody does not comprise an element selected from the group consisting of a radioactive isotope, toxic peptide, and toxic small molecule.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9447185B2 cover?
- The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
- Who is the assignee on this patent?
- Romagne Francois, Moretta Alessandro, Blery Mathieu, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/28. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).